Jazz Pharmaceuticals (JAZZ) investor relations material

Executive summary

• Achieved record quarterly revenue of $1.13 billion in Q3 2025, driven by strong growth in Xywav, Epidiolex, and the launch of Modeyso, with continued pipeline expansion and strategic acquisitions including Chimerix.

• Secured FDA approvals for Modeyso (first for recurrent H3 K27M-mutant DMG) and Zepzelca plus atezolizumab for first-line maintenance in small cell lung cancer, both now included in NCCN guidelines.

• Completed acquisition of Chimerix and entered a global licensing agreement with Saniona for SAN2355, expanding the epilepsy and oncology pipelines.

• Settled all Xyrem antitrust and Avadel litigation, removing key legal uncertainties and impacting SG&A expenses.

• Welcomed Dr. Ted Love to the Board of Directors, enhancing leadership depth.

Financial highlights

• Q3 2025 revenue reached $1.13 billion, up 7% year-over-year, with Xywav sales up 11% to $431 million and Epidiolex up 20% to $303 million.

• Oncology product revenue increased 1% year-over-year, with Modeyso generating $11 million in its launch quarter.

• Adjusted net income for Q3 was $501 million ($8.13 per share); GAAP net income was $251.4 million ($4.08 per share).

• Gross margin for Q3 2025 was 87.9% (GAAP) and 92.2% (non-GAAP); net income margin was 22.3%.

• Cash and investments totaled $2 billion at quarter end, with $993 million in operating cash flow for the first nine months of 2025.

Outlook and guidance

• 2025 revenue guidance narrowed to $4.175–$4.275 billion, with non-GAAP adjusted net income projected at $475–$525 million and EPS guidance raised to $7.65–$8.45.

• Guidance reflects lower litigation costs, portfolio optimization, and anticipated generic entry for Xyrem in 2026.

• Gross margin expected at 88% (GAAP) and 92% (non-GAAP) for the year.

• Top-line results from the phase III Zanidatamab HERIZON-GEA trial expected later this quarter.